Table 2

Clinical characteristics of patients

Patient

Age in years

Gender

Disease duration in years

Anti-SSA/Anti-SSB/RF

Extraglandular manifestations

Prednisolone (mg/day)

Adverse events

1^a

59

Female

13

+/+/+

Arthralgia

-

Vertigo, perspiration

2

46

Female

12

+/+/+

LP, RS

-

GI discomfort, common cold

3^a

50

Female

15

+/+/+

Arthralgia, RS, LP

-

GI discomfort

4

67

Female

17

+/+/+

Arthralgia, RS

2.5

None

5

60

Female

4

+/+/+

Arthralgia, LP, VA

-

GI discomfort^b

6^a

61

Female

5

+/+/+

Arthralgia, LP

-

Pneumonia

7

53

Female

13

+/-/+

LP, PNP

2.5

GI discomfort, herpes labialis

8

40

Female

2

+/-/-

Arthralgia, LP

-

None

9

35

Female

12

+/-/+

LP, RS

5

None

10

44

Female

9

+/+/+

Arthralgia, RS

-

Palpitation, perspiration^b

11

36

Female

2

+/+/-

Arthralgia

-

Common cold

^aPatients 1, 3, and 6 did not complete the study; ^bdose was reduced to 720 mg/day after week 12. GI, gastrointestinal; LP, leukopenia; PNP, polyneuropathy; RF, rheumatoid factor; RS, Raynaud syndrome; VA, vasculitis.

Willeke et al. Arthritis Research & Therapy 2007 9:R115   doi:10.1186/ar2322